Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders

Bernardo Dell'Osso, Laura Cremaschi, Carlotta Palazzo, Neva Suardi, Gregorio Spagnolin, Giulia Camuri, Beatrice Benatti, Lucio Oldani, Cristina Dobrea, Chiara Arici, Giovanna Pace, Alessandra Tiseo, Ester Sembira Nahum, Filippo Castellano, Nazario D'Urso, Massimo Clerici, Diego Primavera, Bernardo Carpiniello, A. Carlo Altamura

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Latency to first pharmacological treatment [duration of untreated illness (DUI)] in psychiatric disorders can be measured in years, with differences across diagnostic areas and relevant consequences in terms of socio-occupational functioning and outcome. Within the psychopathological onset of a specific disorder, many factors influence access and latency to first pharmacotherapy and the present study aimed to investigate such factors, through an ad-hoc developed questionnaire, in a sample of 538 patients with diagnoses of schizophrenia-spectrum disorder (SZ), mood disorder (MD), and anxiety disorder (AD). Patients with SZs showed earlier ages at onset, first diagnosis and treatment, as well as shorter DUI compared with other patients (43.17 months vs. 58.64 and 80.43 months in MD and AD; F=3.813, P=0.02). Patients with MD and AD reported more frequently onset-related stressful events, benzodiazepines as first treatment, and autonomous help seeking compared with patients with SZs. In terms of first therapist, psychiatrist referral accounted for 43.6% of the cases, progressively decreasing from SZ to MD and AD (57.6, 41.8, and 38.3%, respectively). The opposite phenomenon was observed for nonpsychiatrist clinician referrals, whereas psychologist referrals remained constant. The present findings confirm the presence of a relevant DUI in a large sample of Italian patients with different psychiatric disorders (5 years, on average), pointing out specific differences, in terms of treatment access and latency, between psychotic and affective patients. Such aspects are relevant for detection of at-risk patients and implement early intervention programs.

Original languageEnglish
Pages (from-to)29-35
Number of pages7
JournalInternational Clinical Psychopharmacology
Volume30
Issue number1
DOIs
Publication statusPublished - Jan 12 2015

Fingerprint

Anxiety Disorders
Schizophrenia
Pharmacology
Mood Disorders
Psychiatry
Referral and Consultation
Therapeutics
Benzodiazepines
Age of Onset
Psychology
Drug Therapy

Keywords

  • Anxiety disorders
  • Duration of untreated illness
  • Latency to treatment
  • Mood disorders
  • Schizophrenia-spectrum disorders

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders. / Dell'Osso, Bernardo; Cremaschi, Laura; Palazzo, Carlotta; Suardi, Neva; Spagnolin, Gregorio; Camuri, Giulia; Benatti, Beatrice; Oldani, Lucio; Dobrea, Cristina; Arici, Chiara; Pace, Giovanna; Tiseo, Alessandra; Nahum, Ester Sembira; Castellano, Filippo; D'Urso, Nazario; Clerici, Massimo; Primavera, Diego; Carpiniello, Bernardo; Carlo Altamura, A.

In: International Clinical Psychopharmacology, Vol. 30, No. 1, 12.01.2015, p. 29-35.

Research output: Contribution to journalArticle

Dell'Osso, B, Cremaschi, L, Palazzo, C, Suardi, N, Spagnolin, G, Camuri, G, Benatti, B, Oldani, L, Dobrea, C, Arici, C, Pace, G, Tiseo, A, Nahum, ES, Castellano, F, D'Urso, N, Clerici, M, Primavera, D, Carpiniello, B & Carlo Altamura, A 2015, 'Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders', International Clinical Psychopharmacology, vol. 30, no. 1, pp. 29-35. https://doi.org/10.1097/YIC.0000000000000049
Dell'Osso, Bernardo ; Cremaschi, Laura ; Palazzo, Carlotta ; Suardi, Neva ; Spagnolin, Gregorio ; Camuri, Giulia ; Benatti, Beatrice ; Oldani, Lucio ; Dobrea, Cristina ; Arici, Chiara ; Pace, Giovanna ; Tiseo, Alessandra ; Nahum, Ester Sembira ; Castellano, Filippo ; D'Urso, Nazario ; Clerici, Massimo ; Primavera, Diego ; Carpiniello, Bernardo ; Carlo Altamura, A. / Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders. In: International Clinical Psychopharmacology. 2015 ; Vol. 30, No. 1. pp. 29-35.
@article{679126434fae4b7a8529e4e1f4289e3a,
title = "Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders",
abstract = "Latency to first pharmacological treatment [duration of untreated illness (DUI)] in psychiatric disorders can be measured in years, with differences across diagnostic areas and relevant consequences in terms of socio-occupational functioning and outcome. Within the psychopathological onset of a specific disorder, many factors influence access and latency to first pharmacotherapy and the present study aimed to investigate such factors, through an ad-hoc developed questionnaire, in a sample of 538 patients with diagnoses of schizophrenia-spectrum disorder (SZ), mood disorder (MD), and anxiety disorder (AD). Patients with SZs showed earlier ages at onset, first diagnosis and treatment, as well as shorter DUI compared with other patients (43.17 months vs. 58.64 and 80.43 months in MD and AD; F=3.813, P=0.02). Patients with MD and AD reported more frequently onset-related stressful events, benzodiazepines as first treatment, and autonomous help seeking compared with patients with SZs. In terms of first therapist, psychiatrist referral accounted for 43.6{\%} of the cases, progressively decreasing from SZ to MD and AD (57.6, 41.8, and 38.3{\%}, respectively). The opposite phenomenon was observed for nonpsychiatrist clinician referrals, whereas psychologist referrals remained constant. The present findings confirm the presence of a relevant DUI in a large sample of Italian patients with different psychiatric disorders (5 years, on average), pointing out specific differences, in terms of treatment access and latency, between psychotic and affective patients. Such aspects are relevant for detection of at-risk patients and implement early intervention programs.",
keywords = "Anxiety disorders, Duration of untreated illness, Latency to treatment, Mood disorders, Schizophrenia-spectrum disorders",
author = "Bernardo Dell'Osso and Laura Cremaschi and Carlotta Palazzo and Neva Suardi and Gregorio Spagnolin and Giulia Camuri and Beatrice Benatti and Lucio Oldani and Cristina Dobrea and Chiara Arici and Giovanna Pace and Alessandra Tiseo and Nahum, {Ester Sembira} and Filippo Castellano and Nazario D'Urso and Massimo Clerici and Diego Primavera and Bernardo Carpiniello and {Carlo Altamura}, A.",
year = "2015",
month = "1",
day = "12",
doi = "10.1097/YIC.0000000000000049",
language = "English",
volume = "30",
pages = "29--35",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders

AU - Dell'Osso, Bernardo

AU - Cremaschi, Laura

AU - Palazzo, Carlotta

AU - Suardi, Neva

AU - Spagnolin, Gregorio

AU - Camuri, Giulia

AU - Benatti, Beatrice

AU - Oldani, Lucio

AU - Dobrea, Cristina

AU - Arici, Chiara

AU - Pace, Giovanna

AU - Tiseo, Alessandra

AU - Nahum, Ester Sembira

AU - Castellano, Filippo

AU - D'Urso, Nazario

AU - Clerici, Massimo

AU - Primavera, Diego

AU - Carpiniello, Bernardo

AU - Carlo Altamura, A.

PY - 2015/1/12

Y1 - 2015/1/12

N2 - Latency to first pharmacological treatment [duration of untreated illness (DUI)] in psychiatric disorders can be measured in years, with differences across diagnostic areas and relevant consequences in terms of socio-occupational functioning and outcome. Within the psychopathological onset of a specific disorder, many factors influence access and latency to first pharmacotherapy and the present study aimed to investigate such factors, through an ad-hoc developed questionnaire, in a sample of 538 patients with diagnoses of schizophrenia-spectrum disorder (SZ), mood disorder (MD), and anxiety disorder (AD). Patients with SZs showed earlier ages at onset, first diagnosis and treatment, as well as shorter DUI compared with other patients (43.17 months vs. 58.64 and 80.43 months in MD and AD; F=3.813, P=0.02). Patients with MD and AD reported more frequently onset-related stressful events, benzodiazepines as first treatment, and autonomous help seeking compared with patients with SZs. In terms of first therapist, psychiatrist referral accounted for 43.6% of the cases, progressively decreasing from SZ to MD and AD (57.6, 41.8, and 38.3%, respectively). The opposite phenomenon was observed for nonpsychiatrist clinician referrals, whereas psychologist referrals remained constant. The present findings confirm the presence of a relevant DUI in a large sample of Italian patients with different psychiatric disorders (5 years, on average), pointing out specific differences, in terms of treatment access and latency, between psychotic and affective patients. Such aspects are relevant for detection of at-risk patients and implement early intervention programs.

AB - Latency to first pharmacological treatment [duration of untreated illness (DUI)] in psychiatric disorders can be measured in years, with differences across diagnostic areas and relevant consequences in terms of socio-occupational functioning and outcome. Within the psychopathological onset of a specific disorder, many factors influence access and latency to first pharmacotherapy and the present study aimed to investigate such factors, through an ad-hoc developed questionnaire, in a sample of 538 patients with diagnoses of schizophrenia-spectrum disorder (SZ), mood disorder (MD), and anxiety disorder (AD). Patients with SZs showed earlier ages at onset, first diagnosis and treatment, as well as shorter DUI compared with other patients (43.17 months vs. 58.64 and 80.43 months in MD and AD; F=3.813, P=0.02). Patients with MD and AD reported more frequently onset-related stressful events, benzodiazepines as first treatment, and autonomous help seeking compared with patients with SZs. In terms of first therapist, psychiatrist referral accounted for 43.6% of the cases, progressively decreasing from SZ to MD and AD (57.6, 41.8, and 38.3%, respectively). The opposite phenomenon was observed for nonpsychiatrist clinician referrals, whereas psychologist referrals remained constant. The present findings confirm the presence of a relevant DUI in a large sample of Italian patients with different psychiatric disorders (5 years, on average), pointing out specific differences, in terms of treatment access and latency, between psychotic and affective patients. Such aspects are relevant for detection of at-risk patients and implement early intervention programs.

KW - Anxiety disorders

KW - Duration of untreated illness

KW - Latency to treatment

KW - Mood disorders

KW - Schizophrenia-spectrum disorders

UR - http://www.scopus.com/inward/record.url?scp=84918775749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918775749&partnerID=8YFLogxK

U2 - 10.1097/YIC.0000000000000049

DO - 10.1097/YIC.0000000000000049

M3 - Article

VL - 30

SP - 29

EP - 35

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 1

ER -